ERYTECH Pharma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERYP research report →
About the company
ERYTECH Pharma S. A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases.
- CEO
- Gil Beyen
- IPO
- 2016
- Employees
- 49
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $47.38M
- P/E
- -0.02
- P/S
- 0.76
- P/B
- 0.02
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1784.31%
- Net Margin
- -1771.34%
- ROE
- -95.68%
- ROIC
- -56.27%
- Revenue
- $0 · 0.00%
- Net Income
- $-228,000 · 99.58%
- EPS
- $-0.01 · 99.67%
- Op Income
- $-2,796,000
- FCF YoY
- 44.19%
- 52W High
- $1.47
- 52W Low
- $0.30
- 50D MA
- $0.86
- 200D MA
- $0.74
- Beta
- 2.13
- Avg Volume
- 148.59K
Get TickerSpark's AI analysis on ERYP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ERYP coverage
Recent articles, reports, and earnings notes.
No research on ERYP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERYP report →Similar companies
Peers in the same neighborhood.